

TRANSFORMING LIVES DELIVERING RESULTS

KNIGHT THERAPEUTICS INC.
TSX: GUD

AUGUST 2026

Forward Looking Statements

This document contains forward-looking statements and forward-looking information for Knight Therapeutics Inc. and its subsidiaries within the meaning of applicable Canadian securities laws. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control, that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

Forward-looking statements are based on assumptions that management considers reasonable at the time they are made, including assumptions relating to industry information, expected market share, pricing, actions of competitors, sales erosion following the expiry of patent or other intellectual property protection, timing of generic entry, expected tender outcomes, and other factors. In particular, forward-looking information regarding Peak Sales reflects assumptions specific to the nature of the Company's activities and may differ materially from actual results.

Factors and risks that could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2025, available on SEDAR+ at ***www.sedarplus.ca****. Knight undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking statements.*

Knight Overview

Building a Solid Foundation Since 2014

Commercial Stage Pharmaceutical Company Focused on Acquiring and In-Licensing Innovative Pharmaceutical Products for Canada and Latin America

$685M
Raised in equity

2019
Acquisition of Grupo Biotoscana, a Latin American pharma company

June 2025
Closed Paladin and Sumitomo transactions

150+ Products
20+ Partners

18%
Adjusted Revenue 5-year CAGR

21%
Adjusted EBITDA 5-year CAGR

Scaling the Platform

By the Numbers

$547M
Adjusted Revenues in TTM Q2-26
43% Growth vs. TTM Q2-25

$98M
Adjusted EBITDA in TTM Q2-26
75% Growth vs. TTM Q2-25

$110M
Cash and Marketable Securities
$87M Net cash


16 agreements
signed for **65+ products**
in past 5 years

$200M+
Current Pipeline
Expected Revenues

$280M
Syndicated Banking
Facilities

Knight is well positioned for its next phase of growth

Our Growth Strategies



1. In-license **late-stage** prescription pharmaceuticals
2. Acquire mature or **"under-promoted"** products from Big Pharma
3. Develop near-term, **low risk / low expense products**
4. Bolt-on acquisitions - **portfolios or companies** to complement current business

Our Footprint

Growing Across Key Markets

$547M
Adjusted Revenue
TTM Q2-26

11 Countries
plus distributors in Central America & Caribbean


800+
Employees

150+ Products
25+ Pipeline & early launch products

20+
Partners

3 Manufacturing Plants
1 R&D Center
1 Regional Distribution Center

ADJUSTED REVENUE BY GEOGRAPHY




Canada expected to be one of largest contributors to revenue and profitability

Our Markets – Sizable & Growing

Pan-American (ex US) represents ~7% of global pharma market

MARKET SIZE AT CONSTANT CURRENCY[1]



Larger market allows Knight to access more licensing and acquisition opportunities.

[1] *Except Argentina*


All information contained in this material is intellectual property of IQVIA and protected by copyright and other protective laws. Reproduction of the information is strictly prohibited, unless previously authorized in writing by IQVIA.

Our Portfolio


Built for Stability and Growth

ADJUSTED REVENUE

BY PRODUCT PORTFOLIO



BY THERAPEUTIC AREA



KEY PRODUCTS BY THERAPEUTIC AREA

Oncology & Hematology

MINJUVI · Akynzeo · TRELSTAR · ORGOVYX · ZYNYZ · Niktimvo (axatilimab-csfr) · Pemazyre (pemigatinib) · Tavalisse · LENVIMA · Aloxi · Abraxane · Halaven · Vidaza · nerlynx · Leprid 7.5 · Xetrane · Palbocil · LADEVINA · Zyvalix · Rembre · Karfib · capebina

Infectious Disease

AmBisome (amphotericin B) liposome for injection · CRESEMBA · Impavido · Aguoort · DOLUFEVIR 50

Neurology

XCOPRI · EXELON · jornay · CREXONT · Qelbree (viloxazine)

Other Specialty

Myfembree · Imvexxy · Bijuva · GEMTESA (vibegron) · Envarsus PA · Wynzora · Salofalk · Budenofalk · Endofalk · Ursofalk · movantik

Refer to the Footnotes & Glossary slide for definitions of non-IFRS measures.

**The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUVI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.*

Our Partners

Partner of Choice for Canada & Latin America








































**The above registered trademarks, or logos, are owned by Knight's partners. For example: Incyte and the Incyte logo are registered trademarks of Incyte.*

Financial Highlights

Revenue Growing in all Therapeutic Areas

ADJUSTED REVENUE BY THERAPEUTIC AREA



2026 Revenue Guidance


Between $540 - $560M

(>20% growth over 2025)

Financial Highlights


Strong Adjusted EBITDA and Cash Flow

ADJUSTED EBITDA



2026 EBITDA Guidance
At least 15% Adjusted Revenues (>10% growth over 2025)

CASH FLOW FROM OPERATIONS



Significant cash generated from EBITDA

Balance Sheet Highlights (June 30, 2026)

Healthy Balance Sheet with Capacity for More Acquisitions

$110M
Cash and Marketable Securities
$1.12/share

$81M
Financial Assets
$0.83/share

$23M
Debt
$0.24/share

0.24 x
Debt to TTM
Adjusted EBITDA


0.31:1
Debt to Equity
Ratio

Credit Available
Line of Credits: **$140M**
Accordion: **$140M**

Capital Allocation

Executing on Acquisitions and NCIB

PRODUCTS & ACQUISITIONS




Biotoscana Acquisition

Exelon Acquisition

Paladin & Sumitomo Acquisitions

SHARE BUYBACK



Over $260M invested in NCIB or over 30% of shares outstanding

Capital Structure

As at Aug 7, 2026

~$959M Market Capitalization	**98.2M** Common Shares Outstanding	**23.4%** Insider Holdings %
~$791M Adjusted Enterprise Value	**$98M** Adjusted EBITDA in TTM Q2-2026	**7.3M** Stock Options and Share Awards

Management Team

Executing on Growth & Performance



Samira Sakhia - Canada
President and Chief Executive Officer
Paladin Labs, Chief Financial Officer
Executed sale of Paladin Labs for over $3 billion



Amal Khouri - Canada
Chief Business Officer
Novartis, Global Business Development and Licensing
Paladin Labs, Business Development
Led multiple regional and global product and M&A transactions of over $1 billion



Arvind Utchanah, CPA - Uruguay
Chief Financial Officer
Paladin Labs, Finance
Ernst & Young, Audit
Managed capital of $1 billion and implemented financial and operational systems optimization in 11 countries



Susan Emblem - Canada
Global VP Human Resources
Paladin Labs, VP Human Resources and Corporate Communications
Led integration of Paladin Labs with Endo International



Monica Percario - Brazil
Global VP Regulatory and Quality
Sanofi, Head of Regulatory and Center of Expertise LATAM
Farmasa (now Hypera Pharma), Regulatory Affairs
Extensive experience with >70 products approved across LATAM including innovative and generic products, biologics and nutraceuticals



Leopoldo Bosano - Argentina
Global VP Manufacturing and Operations
Givaudan, Bristol Myers Squibb
Led several manufacturing sites across LATAM including restructuring and supply chain optimization



Cristina Viayna - United States
Global VP Marketing
Novartis, Therapeutic Area Head, Immunology LACan
Sandoz, Commercial Head, LatAm
Led portfolio strategy, launches and licensing across LATAM and Canada across innovative & established brands, branded generics & biosimilars



Melanie Groleau - Canada
Global VP Medical and Clinical
Sanofi, Head of Business Planning in Commercial and Scientific Affairs
Pharmacist with 25 years of experience in health care system and pharmaceutical industry

Board Members

Proven Track Record



Jonathan Ross Goodman
Executive Chairman
Knight Therapeutics, Founder
Paladin Labs, Co-founder, former President & CEO



James C. Gale
Lead Director
Paladin Labs, Board member from 2008 to 2014
Signet Healthcare Partners, Managing Director



Samira Sakhia
Knight Therapeutics, President and CEO
Paladin Labs, CFO from 2001 to 2015



Robert N. Lande
Paladin Labs, Board member from 1995 to 2014
Stratos Global International LLC, President



Michael J. Tremblay
Former President of Astellas Canada
Former Chairman of Innovative Medicines Canada



Janice Murray
Former President of Novartis Canada
Former CFO of Novartis Latin America and Canada region



Nicolás Sujoy
Clara Capital Partners, Founding Partner
Former Director of Advent International

Knight's Future Growth

Keep Growing, Keep Adding



Key Achievements – since January 2024

Going from Pipeline to Growth

50+ New Products

- Added Paladin assets – 40+ products
- Added Sumitomo assets – 6 products
- Crexont®
- Onicit®
- Three branded generic products
- Zynyz®
- Niktimvo®

Submissions

- Tavalisse®
- Crexont®
- Minjuvi® - FL
- Niktimvo®
- Gemtesa®

Approvals

- Minjuvi® – DLBCL
- Minjuvi® – FL
- Jornay PM®
- Tavalisse®
- Pemazyre®
- Rembre®
- Wynzora®
- Bapocil®
- Akynzeo®

Launches

- Minjuvi® – DLBCL
- Minjuvi® – FL
- Imvexxy® & Bijuva®
- Jornay PM®
- Pemazyre®
- Re-launched Onicit®
- Re-launched Myfembree® & Orgovyx®
- Re-launched Xcopri®
- Bapocil®
- Tavalisse®
- Molapib®
- Wynzora®

A Proven Business Model

Focused on Delivering Results

Proven Scaled Platform

- ► Canada & Latin America footprint
- ► Proven record to build portfolio
- ► Proven record of launch excellence

Strong Investment Foundation


- ► Disciplined capital allocation
- ► Strong balance sheet
- ► Experienced management team

Clear Path Forward

- ► Deliver launches & pipeline
- ► Expand product portfolio
- ► Drive long-term growth

Progress Toward $200M+

Peak Revenue Guidance



Well positioned to deliver sustained growth and shareholder value

Footnotes & Glossary

(1) Adjusted Revenue, Adjusted EBITDA, and Adjusted EBITDA per share are non-IFRS measures and do not have any standardized meaning under IFRS. As a result, the information presented may not be comparable to similar measures presented by other companies. **Refer to Financial Results under Non-IFRS measures in the Management Discussion & Analysis filed on www.sedarplus.ca for additional details.**

(2) Adjusted Revenue is defined as Revenue excluding the impact of hyperinflation under IAS 29.

(3) Adjusted EBITDA is defined as EBITDA excluding hyperinflation under IAS29, acquisition and transaction costs, and non-recurring expenses.

(4) Adjusted EBITDA per share is defined as Adjusted EBITDA over number of common shares outstanding at the end of the respective period.

(5) EBITDA is defined as operating income or loss adjusted to exclude amortization and impairment of non-current assets, depreciation, but to include costs related to leases.

(6) The Company categorizes its revenues by product portfolio, as defined as follows:

- Promoted - Launched Pipeline Products: Promoted products currently in the early stage of launch, typically having been introduced to the market within the past five years.
- Promoted - Strategic Products: Promoted products that have reached, or are approaching, their peak potential, typically having been introduced to the market over five years ago.
- Mature: Products that require lower levels of promotional activity and/or have reached their peak potential.
- Discontinued: Products that the Company has stopped commercializing or is in the process of discontinuing.



TRANSFORMING LIVES DELIVERING RESULTS

KNIGHT THERAPEUTICS INC.
TSX: GUD

AUGUST 2026